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Abstract
Background:  Public drug insurance plans provide limited reimbursement for Alzheimer's disease (AD)
medications in many jurisdictions, including Canada and the United Kingdom. This study was conducted to assess
Canadians' level of support for an increase in annual personal income taxes to fund a public program of
unrestricted access to AD medications.
Methods: A telephone survey was administered to a national sample of 500 adult Canadians. The survey
contained four scenarios describing a hypothetical, new AD medication. Descriptions varied across scenarios: the
medication was alternatively described as being capable of treating the symptoms of cognitive decline or of halting
the progression of cognitive decline, with either no probability of adverse effects or a 30% probability of primarily
gastrointestinal adverse effects. After each scenario, participants were asked whether they would support a tax
increase to provide unrestricted access to the drug. Participants who responded affirmatively were asked whether
they would pay an additional $75, $150, or $225 per annum in taxes. Multivariable logistic regression analysis was
conducted to examine the determinants of support for a tax increase.
Results: Eighty percent of participants supported a tax increase for at least one scenario. Support was highest
(67%) for the most favourable scenario (halt progression - no adverse effects) and lowest (49%) for the least
favourable scenario (symptom treatment - 30% chance of adverse effects). The odds of supporting a tax increase
under at least one scenario were approximately 55% less for participants who attached higher ratings to their
health state under the assumption that they had moderate AD and almost five times greater if participants thought
family members or friends would somewhat or strongly approve of their decision to support a tax increase. A
majority of participants would pay an additional $150 per annum in taxes, regardless of scenario. Less than 50%
would pay $225.
Conclusions: Four out of five persons in a sample of adult Canadians reported they would support a tax increase
to fund unrestricted access to a hypothetical, new AD medication. These results signal a willingness to pay for at
least some relaxation of reimbursement restrictions on AD medications.
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Background
Alzheimer's disease (AD) is a neurodegenerative disorder
that is characterized by progressive decline in cognitive
and functional abilities. Early symptoms include loss of
short-term memory, immediate event recall, and atten-
tion. Over time, patients lose the ability to perform activ-
ities of daily living [1]. The negative health impact of AD
has been increasing relative to other chronic diseases in
recent years. Between 2000 and 2006, deaths attributable
to AD in the United States alone increased by 47%, while
deaths attributable to heart disease, stroke, and prostate
cancer decreased during the same time period [2]. Medi-
cations are the primary means of treating AD [3]. Existing
medications have been shown to symptomatically treat
cognitive decline for periods of up to one year, but they do
not modify the course of disease [4]. Four medications are
currently used to treat AD: donepezil, rivastigmine, and
galantamine are part of a class of drugs called cholineste-
rase inhibitors (ChEIs); memantine is an N-methyl-D-
aspartate receptor antagonist.
The modest efficacy of the four approved AD medications
has led the administrators of public drug plans to develop
evidence-based guidelines that generally permit patients
to be reimbursed for the cost of these medications under
certain conditions. For example, the Ontario Drug Benefit
Program will reimburse donepezil for an initial three-
month period if patients have a Mini-Mental State Exam-
ination (MMSE) [5] score of 10 to 26, which indicates
mild or moderate AD. Continuation of reimbursement
requires the MMSE to be re-administered at three-month
intervals, with patients required to maintain a score
between 10 and 26. Reimbursement may continue for a
maximum period of one year [6]. Evidence suggests
donepezil is not efficacious in persons with severe AD, so
MMSE scores must be indicative of mild or moderate AD
for reimbursement to continue.
Estimates from the Canadian Study of Health and Aging
suggest that the prevalence of AD in the Canadian popu-
lation will increase five-fold by 2031. Comparatively, the
total Canadian population is expected to increase by a fac-
tor of only 1.4 during this same period [7]. Given the bur-
den of AD on patients, caregivers, families [8], and
society, reimbursement is an important issue for the pub-
lic and policy makers to consider. Reimbursement is also
important because AD is a chronic condition and the cost
of drug treatment beyond a limited reimbursement period
must be covered 'out-of-pocket'. Reimbursement will take
on further importance as the first generation of disease
modifying AD medications comes on the market in the
next few years. However, it is currently unknown whether
the general public would support funding unrestricted
access to AD medications. This is especially important in
countries like Canada, where the general public essen-
tially funds the public healthcare system and forms the
pool of future potential patients. To gauge the general
public's view on reimbursement in light of these issues,
and to guide policy makers in decision making, a national
survey of adult Canadians was undertaken to assess the
level of support for an increase in annual personal income
taxes to fund a public program of unrestricted access to
AD medications. To enrich the understanding of support
for a tax increase, participants who said they would sup-
port the increase were asked about paying specific dollar
amounts in tax.
Methods
Sample
The sample consisted of 500 Canadians, aged 18 years or
over, who were chosen randomly from all 10 provinces.
The sample was selected using ASDE Survey Sampler
(ASDE Survey Sampler Inc., Gatineau, QC, Canada),
which utilizes random digit dialling methodology to
choose a sample of telephone numbers of potential par-
ticipants.
Selection bias due to income could result if different pro-
portions of high and low income groups participate in the
survey and the likelihood of supporting a tax increase dif-
fers by group. To eliminate this potential selection bias,
the sample was stratified into five income categories, each
of which contained 100 participants. The five categories
were: less than $20,000; $20,000 to less than $40,000;
$40,000 to less than $60,000; $60,000 to less than
$80,000; and $80,000 or more (all values in Canadian
dollars).
Survey
The data collection instrument was a two-part question-
naire. The first part contained questions on sample char-
acteristics, e.g., age, sex, income, level of education,
employment status. The first part also included the AD
Knowledge Test (ADKT) [9] and the EQ-5D [10]. The
ADKT has five true or false questions. Zero points are
awarded for each 'true' response and one point is awarded
for each 'false' response. Points are totalled and higher
scores indicate a better knowledge of AD. The EQ-5D is a
standardized instrument for measuring general health sta-
tus, with questions on mobility, self-care, usual daily
activities (e.g., work), pain and discomfort, and anxiety
and depression. EQ-5D question responses were con-
verted into an overall health utility index using United
States population-based preference weights [11]. This
index ranges from -0.11 (a health state worse than death)
to 1.0 (perfect health). An index value of 0.0 is equivalent
to death. The EQ-5D was administered twice in the ques-
tionnaire. For the first administration, participants were
asked to rate their own health state today. For the second
administration, participants were given a description ofBMC Health Services Research 2009, 9:246 http://www.biomedcentral.com/1472-6963/9/246
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what may happen to persons with moderate AD (e.g.,
memory loss, increased dependence on caregivers) and
they were asked to re-answer the EQ-5D under the
assumption that they had moderate AD. Other questions
in the survey included asking participants if they had any
family members or close friends with AD, as well as
whether family members or friends would approve of
their decision to support a tax increase.
The second part of the survey consisted of four 'efficacy'
scenarios describing a hypothetical, new AD medication.
In two scenarios, the medication was described as treating
the symptoms of cognitive decline. This is akin to the effi-
cacy of the ChEIs and memantine. In the other two scenar-
ios, the medication was described as halting disease
progression (disease modification). For each pair of 'effi-
cacy' scenarios, the medication was assumed to have no
adverse effects in one scenario and a 30% chance of
adverse effects in the other scenario. The adverse effects
were described as primarily gastrointestinal in nature
(e.g., vomiting, nausea, diarrhea).
For every scenario, participants were asked whether they
would support unrestricted access to the medication
through an annual increase in personal income taxes. Par-
ticipants who responded affirmatively were asked in a sep-
arate set of questions whether they would pay $75, $150,
or $225 per annum in additional personal income taxes.
The middle value of $150 was the equivalent Canadian
cost of supplying one person with existing, approved AD
medications for one month. Only participants who indi-
cated they would support unrestricted access were asked
about specific dollar amounts (bids) to avoid 'yeah say-
ing' bias, where someone would accept any bid as a means
of expressing support for the program in question [12]. In
the event a participant did accept all three bids, an open-
ended question was asked to elicit the maximum amount
they would be willing to pay. For participants who sup-
ported a program of unrestricted access and rejected each
of the three bids, an open-ended question was asked to
obtain a value between $0 and $74.
Our process of presenting bids to participants was based
on the contingent valuation literature's dissonance mini-
mizing methodology (coupled with a bid range). Disso-
nance minimization involves the use of two sets of
questions: a preliminary question without a bid value to
ascertain whether participants support a program and a
follow-up question to assess whether participants support
a specific bid. Participants who answer the preliminary
question affirmatively will move on to answer the bid
question. The purpose of this tiered approach is to avoid
yeah-saying bias. In another method, known as dichoto-
mous choice, participants are presented with a single
question containing a bid that they accept or reject. We
avoided dichotomous choice to guard against yeah-saying
bias.
In both dissonance minimization and dichotomous
choice, each participant is often presented with a single
bid. Thus, large sample sizes are required to obtain ranges
of support across different bids. We reduced the sample
size requirement by asking each participant to accept or
reject a range of different bids.
Survey design and administration
The content of the survey was developed by the authors in
accordance with the results of a recent systematic review of
AD studies in the contingent valuation literature [13]. The
wording of the questions and response options was based
on the principles of survey design [14]. The survey was
pretested on 45 members of the general public. Interview-
ers administered the pretest over the telephone as though
they were doing 'real' interviews. The purpose of the pre-
test was to note and correct challenges with question flow,
skip patterns, and response options, as well as to elicit par-
ticipant feedback on issues such as unclear question word-
ing.
The final version of the survey was administered by
trained interviewers to study participants via Computer-
Assisted Telephone Interviewing (CATI) technology. Par-
ticipants were randomized to the order of scenarios and to
the order of bids to prevent ordering and starting point
bias. A minimum of seven attempts was made per tele-
phone number to complete the interview, after which the
contact was classified as a non-respondent.
Since the survey was administered to French-speaking per-
sons in the Province of Québec, the final English-language
version of the survey was translated into French. The
translation was verified by a bilingual co-author (JET). A
copy of the English version of the survey is included as an
appendix (see Additional file 1).
The study protocol and survey received ethics approval
from the Hamilton Health Sciences/McMaster Faculty of
Health Sciences Research Ethics Board (reference number:
08-179).
Statistical analysis
Descriptive statistics were calculated for all variables.
These statistics included frequencies for categorical varia-
bles and medians and 25th to 75th percentile ranges for
continuous variables.
A logistic regression analysis was conducted to examine
the determinants of support for a tax increase. The pri-
mary outcome variable was dichotomous: a participant
supports a tax increase under at least one scenario or doesBMC Health Services Research 2009, 9:246 http://www.biomedcentral.com/1472-6963/9/246
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not support a tax increase under any scenario. This varia-
ble was chosen to assess participants' overall openness to
the idea of supporting a tax increase. Based on the afore-
mentioned review of contingent valuation papers in AD
[13], 11 possible explanatory variables were selected for
use in regression modeling (Table 1). Continuous varia-
bles were assessed to see if they were linear in the logit
using the procedure outlined by Hosmer and Lemeshow
[15]. If not, then these variables were categorized at the
quartile(s) where the direction of effect appeared to
change.
Univariable logistic regression analyses were conducted to
examine the effect of each individual variable in Table 1.
A full, multivariable logistic regression model was built
using the following rules: age, sex, and income were
forced into the model regardless of their levels of signifi-
cance in the univariable regression analyses; the remain-
Table 1: Sample characteristics
Characteristic n%
Sex
Female 305 61
Male 195 39
Annual household income
<$20,000 100 20
$20,000 to <$40,000 100 20
$40,000 to <$60,000 100 20
$60,000 to <$80,000 100 20
≥ $80,000 100 20
Region of residence
Atlantic 36 7
Québec 155 31
Ontario 167 33
Prairies 83 17
British Columbia 59 12
Highest level of education completed
High school or less 169 34
At least some technical or community college 143 29
At least some university 184 37
Missing 4< 1
Employment status
Not working (unemployed, student, homemaker) 66 13
Retired 142 28
Employed (full- or part-time) 281 56
Missing 11 2
Participant knows a family member or close friend with Alzheimer's disease
Yes 211 42
No 286 57
Missing 3< 1
Family members' or friends' level of approval of a participant's decision to support a tax increase*
Strongly disapprove 39 8
Somewhat disapprove 78 16
Somewhat approve 260 52
Strongly approve 110 22
Missing 13 3
Alzheimer's disease knowledge score† 4** 3 to 4††
Age‡ 51** 40 to 64††
EQ-5D Index (current health state)¶ 0.83** 0.80 to 1.00††
EQ-5D Index (participants assume they have Alzheimer's disease)§ 0.68** 0.47 to 0.77††
*This is the participant's belief in whether a family member or friend would approve of their decision to support a tax increase. It is not the 
participant's actual knowledge of whether family or friends would approve.
†Not linear in the logit: categorized for regression analyses as good (score = 4 to 5), fair (score = 2 to 3), poor (score = 0 to 1).
‡Not linear in the logit: categorized for regression analyses as <65 years, ≥ 65 years.
¶Not linear in the logit: categorized for regression analyses as <0.84, ≥ 0.84.
§Not linear in the logit: categorized for regression analyses as <0.78, ≥ 0.78.
**Median.
††25th to 75th percentile.BMC Health Services Research 2009, 9:246 http://www.biomedcentral.com/1472-6963/9/246
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ing variables were included in the full model if their p-
values (Wald chi-square) were ≤ 0.20 in the univariable
regression analyses. The full model was paired down into
a reduced model. The following rules were used to deter-
mine the variables that would be retained in the reduced
model: age, sex, and income were automatically retained;
variables with a p-value < 0.05 in the univariable regres-
sion analyses; and variables with a p-value < 0.05 in the
full model.
The full and reduced models were compared with one
another using the likelihood ratio test and Akaike Infor-
mation Criterion (AIC). Model fit was assessed using the
Hosmer and Lemeshow Goodness-of-fit test. Variables
were considered statistically significant at the 5% level (α
= 0.05). SAS v9.1 (The SAS Institute, Cary, NC) was used
to conduct all statistical analyses.
We used McNemar's test to compare whether the number
of participants in each scenario who accepted bids other
than $75 was statistically significantly different from the
number who accepted the $75 bid.
A series of exploratory analyses were also conducted to
investigate whether the determinants of support for a tax
increase differed by individual scenario. For each of the
four scenarios, full and reduced multivariable logistic
regression models were built using the same steps as out-
lined above.
Results
Sample characteristics and descriptive statistics
A total of 13,195 unique telephone numbers were dialled
to obtain 500 participants. Out of the total dialled, 8,718
(66%) did not generate participants for 'process' reasons
(e.g., no answer, busy signal, not in service), 2,460 (19%)
led to persons who refused participation or terminated an
in-progress interview, 273 (2%) led to persons who were
rejected because the 100-participant income quota for the
stratum into which they fit had been reached, 92 (<1%)
led to persons who refused to provide their income, and
1,112 (8%) resulted in scheduled call-backs that were
unneeded after having already achieved the required sam-
ple size. The remaining 540 telephone numbers (4%) led
to completed interviews. The 40 interviews above the
required 500 were conducted to correct a regional sam-
pling disparity, which produced no initial representation
from Québec in the highest income stratum. After the 40
additional interviews, the highest income stratum con-
tained 140 participants, out of which 100 were chosen via
a simple random sample for inclusion in the analysis.
The median age of the 500 participants was 51 years (25th
to 75th percentile range: 40 to 64) and 61% were female.
Thirty-seven percent had at least some university educa-
tion, 57% were employed full- or part-time, and 42%
knew a family member or close friend with AD. Table 1
shows more characteristics of the sample.
Eighty percent of participants (n = 398) supported a tax
increase for at least one scenario. Support for a tax
increase at the level of specific scenarios ranged from 49%
to 67% (Figure 1). Support was highest for the most
favourable scenario (disease modifying medication with-
out adverse effects) and lowest for the least favourable sce-
nario (medication treats symptoms only and has a 30%
chance of adverse effects). When stratified by adverse
effects profile (no adverse effects versus 30% chance), sup-
port was highest for the disease modifying version of the
medication. When stratified by type of efficacy, support
was highest for the medication without adverse effects.
In univariable logistic regression analyses, five variables
had p-values ≤ 0.20: AD knowledge score, EQ-5D index
scores for participants' current health states and their
assumed health states if they had AD, whether they knew
a family member or close friend with AD, and whether
family or friends would approve participants' decisions to
support a tax increase. The full model included these five
variables and age, sex, and income. The reduced model
included all of the variables from the full model except
AD knowledge score and the EQ-5D index score for par-
ticipants' current health states.
In the full and reduced logistic regression models for sup-
porting a tax increase under at least one scenario, the only
two variables that were statistically significant at the 5%
level were EQ-5D index score (participants assume they
have moderate AD) and relatives' or friends' approval of
participant support for a tax increase. Although both the
full and reduced models were a good fit to the data, the
full model was preferred over the reduced model based on
the likelihood ratio test and AIC. The results of both mod-
els are summarized in Table 2.
Based on the models in Table 2, the odds of supporting a
tax increase under at least one scenario were approxi-
mately 55% less for participants who attached higher rat-
ings to their health state (i.e., EQ-5D ≥ 0.78) under the
assumption they had moderate AD, relative to partici-
pants who attached lower ratings (i.e., EQ-5D < 0.78). If
participants thought family members or friends would
somewhat or strongly approve of their decision to support
a tax increase, then the odds of actually supporting a tax
increase under at least one scenario would increase by
approximately five times or more, relative to situations
where family or friends were thought to strongly disap-
prove. The odds ratios and confidence intervals for these
two variables were consistent across both the full and
reduced models.BMC Health Services Research 2009, 9:246 http://www.biomedcentral.com/1472-6963/9/246
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In the exploratory regression analyses pertaining to deter-
minants of support for a tax increase under each individ-
ual scenario (Table 3), family members' or friends'
approval of a participant's decision to support a tax
increase was statistically significant at the 5% level in all
full and reduced models. The results were consistent
across the four scenarios and the odds ratios were similar
to the models shown in Table 2. EQ-5D score under the
assumption that participants had moderate AD was signif-
icant at the 5% level in the scenario involving a medica-
tion that treats symptoms and has no adverse effects. The
direction of effect for EQ-5D score was negative (odds
ratio [OR] = 0.57; 95% confidence interval [CI] = 0.34 to
0.93 [reduced model]). Participants aged 65 years or more
were less likely than participants aged less than 65 years to
support a tax increase when the medication treated symp-
toms and had a 30% chance of adverse effects (OR = 0.58;
95% CI = 0.32 to 0.99 [reduced model only]).
For the scenario involving a disease modifying medica-
tion with a 30% chance of adverse effects, three variables
explained support for a tax increase in addition to 'family
member or friend approval' (all results from reduced
model): good versus poor knowledge of AD (OR = 0.17;
95% CI = 0.03 to 0.90) and fair versus poor knowledge of
AD (OR = 0.15; 95% CI = 0.03 to 0.78); age 65 years or
more versus less than 65 years (OR = 0.45; 95% CI = 0.25
to 0.80); and income of $60,000 to less than $80,000 ver-
sus less than $20,000 (OR = 2.37; 95% CI: 1.17 to 4.81).
Table 3 shows the variables that were significant at the 5%
level in the scenario-specific models. Specific model
details are available from the authors upon request.
Among the participants who supported a tax increase
under each scenario, at least 86% reported they would pay
$75 extra per annum for a program of unrestricted access
to AD medications. Approximately two-thirds would also
pay $150, and just under half would pay $225 (Figure 2;
p < 0.05 for all dollar-value comparisons against $75).
Discussion
Eighty percent of participants supported a tax increase,
under at least one of four scenarios, to fund unrestricted
access to a hypothetical, new AD medication. Support was
Support for an increase in annual personal income tax to fund a program of unrestricted access to Alzheimer's disease medica- tions -- specific scenarios Figure 1
Support for an increase in annual personal income tax to fund a program of unrestricted access to Alzheimer's 
disease medications -- specific scenarios. Proportion of participants in favour of support for an increase did not differ by order of 
randomization: Symptom treatment, no adverse effects:   = 29.62, p = 0.16. Symptom treatment, 30% chance of adverse 
effects:   = 23.07, p = 0.42. Disease modification, no adverse effects:   = 22.15, p = 0.51. Disease modification, 30% 
chance of adverse effects:   = 32.67, p = 0.09.
  0.67* 
  0.58 
  0.54
†
0.49*
*p < 0.01 compared to symptom 
treatment, no adverse effects 
†p = 0.06 compared to symptom 
treatment, no adverse effects 
X23
2
X23
2 X23
2
X23
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highest for the most favourable scenario, in which the
medication was described as modifying the course of dis-
ease without entailing adverse effects.
A majority of participants would be willing to pay an
additional $150 per annum in personal income taxes to
fund unrestricted access to the medication. Just under half
of the participants would also be willing to pay more than
$225 per annum. For an average, single Canadian without
children who earns $40,000 per annum and has an
annual tax burden of 25% of income (i.e., $10,000 paid
in taxes) [16], an extra $150 would translate into a 1.5%
increase in tax burden.
This is the first study in Canada or elsewhere to assess
whether the general public would pay more taxes to liber-
alize public reimbursement regimes for AD medications.
In a recent systematic review [13], two of the authors
(MO, JET) could only find one other study of taxation and
publicly-subsidized programs in AD. This study, by
Nocera et al. [17], involved 1,240 German-speaking per-
sons in Switzerland who were aged 18 years or more and
selected randomly from a telephone book. Three AD pro-
grams were assessed: two-day training for unpaid caregiv-
ers and free access to a nurse professional for four weeks
annually; early screening; and intensified research in
Swiss universities. Participants' support was assessed for
various specific levels of taxation, e.g., would a participant
Table 2: Multivariable logistic regression analysis -- participant support for a tax increase under at least one scenario
Models
Variables Full
OR (95% CI)
Reduced
OR (95% CI)
Alzheimer's disease knowledge score
Good 0.27 (0.03-2.46) NIM
Fair 0.24 (0.03-2.15) NIM
Poor 1.00 NIM
Age
≥ 65 years 1.15 (0.56-2.33) 1.25 (0.63-2.49)
< 65 years 1.00 1.00
Sex
Female 0.99 (0.57-1.71) 0.96 (0.56-1.64)
Male 1.00 1.00
EQ-5D Index (current health state)
≥ 0.84 1.25 (0.73-2.14) NIM
< 0.84 1.00 NIM
EQ-5D Index (participants assume they have Alzheimer's disease)
≥ 0.78 0.47 (0.26-0.85) 0.43 (0.24-0.77)
< 0.78 1.00 1.00
Annual household income
≥ $80,000 1.04 (0.41-2.62) 1.19 (0.49-2.88)
$60,000 to < $80,000 1.10 (0.44-2.72) 1.25 (0.52-2.99)
$40,000 to < $60,000 0.48 (0.21-1.09) 0.53 (0.24-1.16)
$20,000 to < $40,000 1.15 (0.36-2.09) 1.09 (0.48-2.50)
< $20,000 1.00 1.00
Family/friend has Alzheimer's disease*
Yes 1.34 (0.77-2.30) 1.28 (0.75-2.19)
No 1.00 1.00
Family/friend approval†
Strongly approve 13.49 (4.30-42.33) 14.72 (4.80-45.21)
Somewhat approve 4.57 (1.96-10.61) 4.82 (2.12-10.95)
Somewhat disapprove 1.50 (0.61-3.71) 1.66 (0.69-4.02)
Strongly disapprove 1.00 1.00
-2 Log likelihood 361.92 369.94
Likelihood ratio test
(reduced model versus full model) G = 8.02;   = 7.82
p = 0.0456
Akaike information criterion 391.92 393.94
Hosmer and Lemeshow Goodness-of- fit Test p = 0.4431 p = 0.3039
OR = odds ratio; CI = confidence interval; NIM = not in model; G = difference in -2 log likelihoods between models.
*Participant knows a family member or close friend with Alzheimer's disease.
†Family members' or friends' level of approval of a participant's decision to support a tax increase.
X23
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support a tax increase of 'X' Swiss francs? Support was
highest for the 'training-and-nurse' program (specific level
of support not reported), followed by research (80% sup-
port) and screening (20% support). Nocera et al. did not
report the percentage of participants who supported at
least one program. The Swiss study, like the current study,
shows that members of the general public do support
increased taxation for AD programs, with the level of sup-
port varying depending on the perceived value of the pro-
gram.
Subsequent to the review, a study by Negrín et al. [18] was
published involving 598 participants selected randomly
from the adult population of the Canary Islands. The par-
ticipants were presented with a mix of three distinct pro-
grams (i.e., home care, access to day care centres, access to
medium- and long-stay centres), combined with a mix of
'monthly contributions' (tax increases) to fund each pro-
gram (i.e., •12, •24, •48, •72). The mix of programs and
contributions was varied for each participant, who was
asked to select the most preferred option from the mix.
Home care was preferred by the majority of participants.
Only 77 participants (13%) said they would not pay any-
thing for these programs.
From a policy making perspective, the results suggest that
Canadians would be likely to support (and pay taxes for)
at least some relaxation of reimbursement restrictions on
AD medications. The most support would flow when
medications modify disease, especially in the absence of
adverse effects. This finding is particularly relevant
because the first disease modifying medications are due
on the market within the next few years. Of course, if a dis-
ease modifying medication without adverse effects were
ever to come on the market, then policy makers would
likely approve it and may even offer unrestricted reim-
bursement, regardless of public opinion.
This study of the Canadian general public has numerous
strengths that lend credence to its findings. First, the par-
ticipants were recruited from a pan-Canadian sampling
frame using a random sampling methodology, thus elim-
inating selection biases associated with region of resi-
dence or location of recruitment (e.g., recruiting visitors to
doctors' offices instead of recruiting a broader, national
sample). Second, data were collected with a standardized
interview that was conducted by trained interviewers
using CATI software to lessen potential information bias.
Third, the order of scenarios, starting bids, and bid ranges
were randomized to prevent ordering or starting point
bias. Ordering bias can occur when participants' answers
to a scenario are influenced by their answers to preceding
scenarios, while starting point bias can occur when
respondents express WTP values that are close to the ini-
tial bids. In an effort to reduce yeah saying and protest
answers, respondents were first asked if they would sup-
port a tax increase. Fourth, the results for supporting a tax
increase for specific scenarios made intuitive sense. Sup-
port was highest for the optimal drug scenario (disease
modification, no adverse effects) and lowest for the least
favourable scenario (symptomatic treatment, 30% chance
of adverse effects). Support was also highest for the small-
est tax increase ($75) and lower for larger tax increases (>
$75) (Figure 2; p < 0.05 for all dollar-value comparisons
versus $75).
In this study, the variable that was most consistently asso-
ciated with support for a tax increase to fund unrestricted
Table 3: Exploratory analyses: summary of regression models
Variable S1 S2 S3 S4
FM RM FM RM FM RM FM RM
Alzheimer's disease knowledge score √√
Age √√ √
Sex
EQ-5D Index (current health state)
EQ-5D Index (participants assume they have Alzheimer's disease) √√
Annual household income* √√
Region of residence
Highest level of education completed
Employment status
Participant knows a family member or close friend with Alzheimer's disease
Family members' or friends' level of approval of a participant's decision to support a tax increase† √√√√√√√√
S1 = scenario 1 (symptom treatment, no adverse effects); S2 = scenario 2 (symptom treatment, 30% chance of adverse effects); S3 = scenario 3 
(disease modification, no adverse effects); S4 = scenario 4 (disease modification, 30% chance of adverse effects); FM = full model; RM = reduced 
model; √ = variable is significant at the 5% level (p < 0.05) in the model.
*Only the '$60,000 to less than $80,000' category (versus 'less than $20,000') is significant at the 5% level.
†Only the 'somewhat approve' and 'strongly approve' categories (versus 'strongly disapprove') are significant at the 5% level.BMC Health Services Research 2009, 9:246 http://www.biomedcentral.com/1472-6963/9/246
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access to AD medications was participants' perceptions
about whether family members or friends would some-
what or strongly approve of their decision to support a tax
increase. Perhaps the favourable views of persons who are
at the core of one's social network could exert a positive
influence on support for a tax increase. Werner et al. [19]
refer to this as 'subjective norm' and found similar results
in a study of 220 caregivers of family members with AD.
The caregivers in the Werner et al. study were found to be
willing to pay more for an AD medication when they
believed their close associates would approve of their pay-
ing for the medication.
Income was not associated with support for a tax increase.
Three reasons could explain this finding. First, effects were
undetectable because the sample was stratified into five
equal-sized income categories to control for possible
selection bias on income. Second, participants' said 'yes'
to the tax support questions to 'do the right thing' or
please the interviewer by giving a socially desirable
Number of participants agreeing to specific annual income tax increases to fund a program of unrestricted access to an Alzhe- imer's disease medication Figure 2
Number of participants agreeing to specific annual income tax increases to fund a program of unrestricted 
access to an Alzheimer's disease medication. Participants may have agreed to more than one of the values in each sce-
nario. The number of participants in each scenario who agreed to values other than $75 was statistically significantly different 
(P < 0.05 [McNemar]) from the number who agreed to $75.
Symptom Treatment – No Adverse Effects 
(n = 296 supported a tax increase)
Symptom Treatment – 30% Chance of Adverse Effects 
(n = 260 supported a tax increase)
Disease Modification – No Adverse Effects 
(n = 338 supported a tax increase)
Disease Modification – 30% Chance of Adverse Effects 
(n = 279 supported a tax increase)BMC Health Services Research 2009, 9:246 http://www.biomedcentral.com/1472-6963/9/246
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response. Third, participants found the program afforda-
ble regardless of income.
Interestingly, 42% of the participants in the Canadian
general public survey knew someone with AD. This may
not be representative of the general Canadian population.
Additionally, participants' median age was 51 years and
23% were 65 years or older, which indicates that the par-
ticipants were an older subgroup of the Canadian popula-
tion (2006 Census: median age = 39.5 years; percentage
aged 65 years or more = 13.7% [20]). Participant charac-
teristics on both variables could suggest that the study's
findings overestimated the percentage of Canadians who
would support a tax increase. For example, participants
who know someone with AD will be aware of the devas-
tation caused by the disease, thus enhancing their predis-
position to support a tax-funded program of unrestricted
access to AD medications. An older sample has an ele-
vated risk for AD. These persons may recognize the chal-
lenges of being on a fixed income when their risk is
highest, so they may be more likely to support a program
of free access to medications.
The potential for overestimation of support for a tax
increase is not actually born out by the data. In multivari-
able regression analyses, the crude association between
knowing someone with AD and support for a tax increase
was eliminated after adjustment for other possible explan-
atory variables. Age is inconsistently associated with sup-
port and it is significant at the 5% level in only three
models that were built for the exploratory analyses. In
these models, age was inversely associated with support.
Perhaps people in upper middle age (who were saving for
retirement) and seniors on fixed incomes were reticent to
support a program that would reduce their personal finan-
cial resources. These persons might have made implicit
risk-benefit calculations and concluded that the risk of
actually getting AD was outweighed by the need to save
money for present or future personal expenditures.
The data in this study are cross-sectional. Therefore, the
direction of effect between some of the variables may be
the reverse of what is hypothesized in the study (reverse
causality). For example, it is possible that a participant's
close family or friends might know that she or he supports
a tax increase. Such knowledge could prompt the
acquaintances to approve the participant's choice after it
has been made. This is the opposite of the hypothesized
direction of effect, which suggests the participant's percep-
tion of family or friends' approval influences the decision
to support a tax increase.
The issue of reverse causality does not apply to all of the
variables, simply due to their nature. For example, a par-
ticipant's age and sex will not be affected by whether she
or he supports a tax increase. Likewise, the number of rel-
atives or friends with AD will probably be unaffected by
one's support, or lack of support, for a tax increase. The
same would be the case for health status on the EQ-5D,
employment status, education, knowledge of AD, region
of residence, or income.
The 4% overall interview completion rate (more than
13,000 telephone numbers dialled to generate 500 inter-
views) must be viewed in the context of the random digit
dialling method. The ASDE Survey Sampler dialled ran-
dom telephone numbers without guarantee that someone
would answer the phone. Out of 13,195 dialled numbers,
66% were not answered, were busy, or were not in service
and did not result in a contact. Since public opinion on
tax support for AD medications is unlikely to be associ-
ated with answering a telephone, the potential for bias in
this regard is likely to be minimal. For similar reasons,
bias is also unlikely in the case of persons who were
rejected because their income fell within a stratum for
which the 100-participant quota was reached or because
they were unneeded after the overall sample size require-
ment was met. Greater potential for bias might result from
persons who refused participation or terminated an in-
progress interview (n = 2,460), or who refused to provide
their income (n = 92). Inclusion of these two groups in
the denominator along with persons who agreed to partic-
ipate (n = 540) creates a more realistic response propor-
tion of 17%. Reasons for refusing to participate or for
hanging-up are many and may well be unrelated to sup-
port for a tax increase (e.g., poor timing of the telephone
call, person who answers the phone never as a rule partic-
ipates in surveys, person perceives that the interview is
taking too long and terminates the call). Although the par-
ticipants were more likely to know someone with AD or
be older than the average Canadian, these traits did not
appear to bias the study results. Similarly, the decision to
refuse to provide an income may not be associated with
one's level of support for a tax increase. Indeed, the poten-
tial confounding effects of income were addressed by
enrolling an equal number of participants in five income
strata.
Certain segments of the population will be excluded from
the sampling frame of a random digit dialling survey
because they do not have a land line-based telephone.
These persons include the homeless, people living in insti-
tutions, and people who use only cellular telephones. The
possibility of bias in excluding these persons is likely to be
minimal. The homeless or persons who are institutional-
ized due to mental or cognitive impairments would not be
in a position to make decisions about supporting a tax
increase, nor might they even pay taxes as a result of their
circumstances. The exclusion of persons who use only cel-
lular telephones would bias the results if they are more orBMC Health Services Research 2009, 9:246 http://www.biomedcentral.com/1472-6963/9/246
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less likely as a group, compared to people with land lines,
to support a tax increase. Currently, there is no evidence
to suggest whether the 'cellular only' group would be dif-
ferent from the 'land-line' group in this respect.
A potential issue in many surveys is social desirability
bias, where participants provide what they believe are
socially acceptable answers to questions or provide
responses that they believe the interviewer wants to hear.
While it is possible that this bias led to an overestimate of
support for a tax increase, it should be noted that partici-
pants were identified through a telephone number, not by
name, and they remained anonymous throughout the sur-
vey. Also, participants had no in-person contact with
interviewers. The anonymous, impersonal nature of the
interviews may have lessened participants' impetus to
provide socially desirable responses because they would
not have had to share unpopular views with peers. Addi-
tionally, non-verbal cues from the interviewer (e.g., nods
of approval, frowns) would not be evident to participants
over the telephone.
The models shown in Table 3 are dissimilar from one
another. Some of the dissimilarity may be the result of the
different sample sizes used to estimate the scenario-spe-
cific models. Sample sizes were based on the number of
participants who said they would support a tax increase
under each scenario. It is also possible that the determi-
nants of support for a tax increase differ across scenarios.
Further research is required to elucidate the nature of the
differences across scenarios.
From a policy making perspective, the data in Figure 2
communicate two important points. First, support for a
tax-funded program of unrestricted access to AD medica-
tions is likely to increase as the efficacy of AD medications
improves. Second, supporters of the program would gen-
erally prefer to pay lower, rather than higher, taxes for the
program, regardless of drug efficacy.
Interestingly, at higher taxation amounts (i.e., $225 or
greater [Figure 2]), the data suggest a 'floor effect' in each
scenario. A subgroup of the population is insensitive to
changes in the range of taxation measured in the study.
Also, another subgroup exists that would balk at paying
ever higher amounts of tax for a program that they sup-
port in principle.
Future research would be advisable to set the study find-
ings into a comparative policy context. For example, a
group of people who are similar to the participants in this
study could be asked whether they would support tax
increases for unrestricted access to medications for AD, as
well as to medications for other diseases, e.g., cardiovas-
cular disease, diabetes. Policy makers require such com-
parative data to guide decision making. Another area of
future research would be to investigate the determinants
of support for specific dollar values of tax increases.
Conclusion
Four out of five persons in a sample of the adult Canadian
general public reported they would support a tax increase
to fund unrestricted access to a hypothetical, new AD
medication. The highest level of support occurred when
the medication was capable of modifying the course of
disease without entailing adverse effects. A majority of the
sample indicated they would be willing to pay an addi-
tional $150 per annum in personal income taxes to fund
unrestricted access. However, willingness decreased for
amounts over $150.
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